• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

年龄相关性黄斑变性继发视网膜下黄斑出血的治疗结局:一项系统评价

Outcomes in the Treatment of Subretinal Macular Hemorrhage Secondary to Age-Related Macular Degeneration: A Systematic Review.

作者信息

Confalonieri Filippo, Ferraro Vanessa, Barone Gianmaria, Di Maria Alessandra, Petrovski Beáta Éva, Vallejo Garcia Josè Luis, Randazzo Alessandro, Vinciguerra Paolo, Lumi Xhevat, Petrovski Goran

机构信息

Department of Ophthalmology, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy.

出版信息

J Clin Med. 2024 Jan 9;13(2):367. doi: 10.3390/jcm13020367.

DOI:10.3390/jcm13020367
PMID:38256501
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10816885/
Abstract

: Subretinal macular hemorrhage (SRMH) secondary to age-related macular degeneration (AMD) is a relatively rare condition in ophthalmology characterized by blood collection between the neurosensory retina and the retinal pigment epithelium (RPE). Without prompt treatment, visual prognosis is poor. A plethora of treatment approaches have been tried over the past years ranging from intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy to direct subretinal surgery, with no conclusive superiority of one over the other. : We conducted a systematic review of the outcomes and treatment modalities of SRMH from inception to 14 June 2022, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA). The level of evidence was assessed for all included articles according to the quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. : A total of 2745 articles were initially extracted, out of which 1654 articles were obtained after duplicates were removed and their abstracts screened. A total of 155 articles were included for full-text review. Finally, 81 articles remained that fulfilled the inclusion criteria. : Even though there are solid results supporting a variety of treatments for SRMH, the best treatment modality has still not been conclusively demonstrated and further research is needed.

摘要

年龄相关性黄斑变性(AMD)继发的视网膜下黄斑出血(SRMH)在眼科中是一种相对罕见的病症,其特征是在神经感觉视网膜和视网膜色素上皮(RPE)之间有血液积聚。若不及时治疗,视力预后较差。在过去几年中,人们尝试了大量的治疗方法,从玻璃体内抗血管内皮生长因子(抗VEGF)单药治疗到直接视网膜下手术,没有一种方法被证明比其他方法具有决定性的优势。

我们按照系统评价和Meta分析的首选报告项目(PRISMA)指南,对截至2022年6月14日的SRMH的治疗效果和治疗方式进行了系统评价。根据推荐分级评估、制定和评价(GRADE)系统的证据质量,对所有纳入文章的证据水平进行了评估。

最初共提取了2745篇文章,去除重复文章并筛选摘要后,获得了1654篇文章。共有155篇文章纳入全文审查。最后,有81篇文章符合纳入标准。

尽管有确凿的结果支持对SRMH采用多种治疗方法,但最佳治疗方式仍未得到确凿证明,需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ef/10816885/23645ce1534e/jcm-13-00367-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ef/10816885/5c84f021555c/jcm-13-00367-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ef/10816885/23645ce1534e/jcm-13-00367-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ef/10816885/5c84f021555c/jcm-13-00367-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ef/10816885/23645ce1534e/jcm-13-00367-g002.jpg

相似文献

1
Outcomes in the Treatment of Subretinal Macular Hemorrhage Secondary to Age-Related Macular Degeneration: A Systematic Review.年龄相关性黄斑变性继发视网膜下黄斑出血的治疗结局:一项系统评价
J Clin Med. 2024 Jan 9;13(2):367. doi: 10.3390/jcm13020367.
2
Current Management of Subretinal Hemorrhage in Neovascular Age-Related Macular Degeneration.新生血管性年龄相关性黄斑变性视网膜下出血的当前管理
Ophthalmologica. 2023;246(5-6):295-305. doi: 10.1159/000534440. Epub 2023 Oct 7.
3
Intraoperative Optical Coherence Tomography in the Management of Macular Holes: State of the Art and Future Perspectives.术中光学相干断层扫描在黄斑裂孔治疗中的应用:现状与未来展望
Biomedicines. 2022 Nov 9;10(11):2873. doi: 10.3390/biomedicines10112873.
4
Fundus Autofluorescence Patterns in Subretinal Hemorrhages Associated with Neovascular Age-Related Macular Degeneration.视网膜下出血与新生血管性年龄相关性黄斑变性相关的眼底自发荧光模式。
Ophthalmologica. 2024;247(1):58-64. doi: 10.1159/000535865. Epub 2023 Dec 19.
5
Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration.手术、组织型纤溶酶原激活物、抗血管生成药物与年龄相关性黄斑变性研究:继发于年龄相关性黄斑变性的黄斑下出血的随机对照试验。
Ophthalmology. 2023 Sep;130(9):947-957. doi: 10.1016/j.ophtha.2023.04.014. Epub 2023 Apr 22.
6
Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial.玻璃体切除术、视网膜下组织纤维蛋白溶酶原激活物和眼内气体治疗渗出性年龄相关性黄斑变性继发的黄斑下出血(TIGER):一项 3 期、泛欧、2 组、非商业、活性对照、观察者设盲、优效性、随机对照手术试验的研究方案。
Trials. 2022 Jan 31;23(1):99. doi: 10.1186/s13063-021-05966-3.
7
[Treatment of macular hematoma complicating AMD by vitrectomy, subretinal r-TPA injection, intravitreal injection of bevacizumab combined with gas tamponade: Report of 4 cases].玻璃体切除术、视网膜下注射重组组织型纤溶酶原激活剂、玻璃体内注射贝伐单抗联合气体填充治疗湿性年龄相关性黄斑变性并发黄斑血肿:4例报告
J Fr Ophtalmol. 2017 Feb;40(2):133-137. doi: 10.1016/j.jfo.2016.07.020. Epub 2017 Feb 9.
8
Antiplatelets and Anticoagulants in Vitreoretinal Surgery: A Systematic Review.玻璃体视网膜手术中的抗血小板药物和抗凝药物:一项系统评价
Life (Basel). 2023 Jun 9;13(6):1362. doi: 10.3390/life13061362.
9
Vitrectomy with subretinal tissue plasminogen activator (r-TPA) and intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) for submacular hemorrhages treatment: Retrospective analysis of 22 cases.玻璃体内视网膜下组织纤维蛋白溶酶原激活物(r-TPA)联合玻璃体腔注射抗血管内皮生长因子(anti-VEGF)治疗黄斑下出血:22 例回顾性分析。
Arch Soc Esp Oftalmol (Engl Ed). 2022 Jul;97(7):391-395. doi: 10.1016/j.oftale.2021.07.006. Epub 2022 Feb 26.
10
Comparison of subretinal versus intravitreal injection of recombinant tissue plasminogen activator with gas for submacular hemorrhage secondary to wet age-related macular degeneration: treatment outcomes and brief literature review.比较重组组织型纤溶酶原激活剂与气体经视网膜下和玻璃体内注射治疗湿性年龄相关性黄斑变性继发的黄斑下出血:治疗结果和简要文献复习。
Int Ophthalmol. 2021 Dec;41(12):4037-4046. doi: 10.1007/s10792-021-01976-x. Epub 2021 Jul 30.

引用本文的文献

1
Pars plana vitrectomy with tissue plasminogen activator for traumatic submacular hemorrhage.玻璃体切割联合组织型纤溶酶原激活剂治疗外伤性黄斑下出血。
Int J Ophthalmol. 2025 Sep 18;18(9):1797-1802. doi: 10.18240/ijo.2025.09.22. eCollection 2025.
2
Cost-Effectiveness of Alternative Treatment Strategies of Subretinal Macular Hemorrhage.视网膜下黄斑出血替代治疗策略的成本效益
Healthcare (Basel). 2025 Jun 29;13(13):1550. doi: 10.3390/healthcare13131550.
3
Oral Antithrombotic Medication Is Associated with Improved Visual Outcomes in Eyes with Submacular Hemorrhage from Wet Age-Related Macular Degeneration.

本文引用的文献

1
Intravitreal r-tPA Injection and Pneumatic Displacement for Submacular Retinal Hemorrhage: A Case Series.玻璃体内注射重组组织型纤溶酶原激活剂及气体置换治疗黄斑下视网膜出血:病例系列
Case Rep Ophthalmol. 2022 Aug 16;13(2):630-637. doi: 10.1159/000526068. eCollection 2022 May-Aug.
2
Visual acuity outcome in patients with subretinal hemorrhage - office procedure vs. surgical treatment.视网膜下出血患者的视力预后——门诊手术与手术治疗对比
Eur J Ophthalmol. 2023 Jan;33(1):506-513. doi: 10.1177/11206721221098208. Epub 2022 May 9.
3
One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
口服抗血栓药物与湿性年龄相关性黄斑变性所致黄斑下出血患者的视力改善相关。
Ophthalmol Sci. 2025 Apr 14;5(5):100796. doi: 10.1016/j.xops.2025.100796. eCollection 2025 Sep-Oct.
玻璃体内注射组织型纤溶酶原激活剂、雷珠单抗及气体治疗息肉状脉络膜血管病变所致黄斑下出血的一年期转归
J Clin Med. 2022 Apr 13;11(8):2175. doi: 10.3390/jcm11082175.
4
CONTRAST-TO-NOISE RATIO IS A USEFUL PREDICTOR OF EARLY DISPLACEMENT OF LARGE SUBMACULAR HEMORRHAGE BY INTRAVITREAL SF6 GAS INJECTION.对比噪声比是预测眼内注入 SF6 气体对大黄斑下出血早期移位的有用指标。
5
Postoperative follow-up of submacular hemorrhage displacement treated with vitrectomy and subretinal injection of tissue plasminogen activator: ultrawide-field fundus autofluorescence imaging in gas-filled eyes.玻璃体切除术联合视网膜下注射组织型纤溶酶原激活剂治疗黄斑下出血移位的术后随访:充气眼超广角眼底自发荧光成像
Jpn J Ophthalmol. 2022 May;66(3):264-270. doi: 10.1007/s10384-022-00910-7. Epub 2022 Mar 9.
6
Visual Outcome after Vitrectomy with Subretinal tPA Injection to Treat Submacular Hemorrhage Secondary to Age-Related Macular Degeneration or Macroaneurysm.玻璃体切割术联合视网膜下注射组织型纤溶酶原激活剂治疗年龄相关性黄斑变性或大动脉瘤继发黄斑下出血后的视力预后
J Ophthalmol. 2021 Dec 30;2021:3160963. doi: 10.1155/2021/3160963. eCollection 2021.
7
Macular Hemorrhage Due to Age-Related Macular Degeneration or Retinal Arterial Macroaneurysm: Predictive Factors of Surgical Outcome.年龄相关性黄斑变性或视网膜动脉大动脉瘤所致黄斑出血:手术结果的预测因素
J Clin Med. 2021 Dec 10;10(24):5787. doi: 10.3390/jcm10245787.
8
Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration.新生血管性年龄相关性黄斑变性患者黄斑下和/或玻璃体积血行玻璃体切除术后的长期预后
J Ophthalmol. 2021 Nov 2;2021:2963822. doi: 10.1155/2021/2963822. eCollection 2021.
9
Associations and Outcomes of Patients with Submacular Hemorrhage Secondary to Age-related Macular Degeneration in the IVAN Trial.IVAN 试验中与年龄相关性黄斑变性相关的黄斑下出血患者的相关性和结局。
Am J Ophthalmol. 2022 Apr;236:89-98. doi: 10.1016/j.ajo.2021.09.033. Epub 2021 Oct 6.
10
Management of submacular massive haemorrhage in age-related macular degeneration: comparison between subretinal transplant of human amniotic membrane and subretinal injection of tissue plasminogen activator.年龄相关性黄斑变性的黄斑下大量出血的处理:人羊膜视网膜下移植与组织型纤溶酶原激活物视网膜下注射的比较。
Acta Ophthalmol. 2022 Aug;100(5):e1143-e1152. doi: 10.1111/aos.15045. Epub 2021 Oct 5.